Saitama Cancer Center

Perioperative Durvalumab for Resectable NSCLC : Updated Outcomes for Japanese Patients in AEGEAN

ABSTRACT In the phase 3 AEGEAN study, perioperative durvalumab plus neoadjuvant chemotherapy significantly improved the primary endpoints of event‐free survival (EFS) and pathological complete response (pCR) in patients with resectable NSCLC versus neoadjuvant chemotherapy alone....

Perceptions and information needs regarding household exposure to anticancer drugs among family members living with patients receiving outpatient chemotherapy in Japan: A qualitative descriptive study

Introduction As outpatient chemotherapy has become increasingly common, family members may be exposed to anticancer drugs in daily life through contact with patients' body fluids and contaminated environments. However, little is known in Japan about family members' perceptions of...

A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)

Abstract Background There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucir...

Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents

Summary The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant‐ineligible newly diagnosed MM (TIE‐NDMM) utilizing eas...

OA03-RF01.10. Distinct Clinical Roles of CK7/CK20 and CDX2 Expression in Esophagogastric Junction Adenocarcinoma

Abstract Topic Esophageal Cancer: Esophageal Carcinogenesis Background Esophagogastric junction (EGJ) adenocarcinoma comprises tumors arising from distinct backgrounds, including Barrett’s esophageal adenocarcinoma and gastric cardia adenocarcinoma. Although CK7/CK20 expression p...

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

BACKGROUND: Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. He...

Circulating effector memory CD8 + T-cells predict tumor shrinkage and reflect wasting conditions and immunity in tocilizumab plus gemcitabine/nab-paclitaxel for mPDAC

Circulating levels of effector memory CD8 + T cells are associated with a better prognosis in patients with metastatic pancreatic ductal adenocarcinoma. The purpose of this study was to assess the effects of effector memory CD8 + T cells on tumor size and wasting conditions. In t...